Sector News

Protagen AG Appoints Bernhard Kirschbaum as New Chairman

July 22, 2016
Life sciences

Protagen AG, a leading specialist in the development of novel diagnostic tests and companion diagnostics (CDx) in the autoimmune field, today announced that Dr. Oliver Schacht, CEO of Curetis N.V., Holzgerlingen, has joined the company’s Supervisory Board.

Additionally, Dr. Bernhard Kirschbaum, former Merck Pharma Executive and member of the Protagen Board since 2015, was elected as the new Chairman, taking over the position from Prof. Dr. Axel Kleemann.

Dr. Schacht successfully completed the IPO of Curetis in November last year, and served previously in executive positions at Epigenomics Inc. Seattle WA, USA and Epigenomics AG, Berlin. He is a member of the Executive Board of BioDeutschland and has a proven track record in the diagnostics industry, with a strong network in the international capital markets, business development, and sales. “Protagen has recently launched its first proprietary CE-IVD marked products and the Protagen platform is able to continuously deliver novel, clinically validated biomarkers in a market that is in need of novel content,” said Dr. Schacht. “I look forward to supporting the management team and board in translating their efforts into a sustainable commercial success.”

Stefan Müllner, CEO of Protagen, added: “Having successfully executed two IPOs in the diagnostic field, Oliver Schacht will provide invaluable guidance for an effective and targeted expansion of our business.”

Bernhard Kirschbaum, new Chairman of the Protagen Board, commented: “I would like to welcome Oliver Schacht in his new role. Oliver is a great addition to the Board and will help us to grow the business in the demanding field of autoimmune diagnostics. Having served as Chairman of the Board for the last 15 years, Axel Kleemann was the key person who shaped Protagen. We would like to sincerely thank him for his long standing commitment and guidance and I am truly sad to see him leave.”

Source: Protagen

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach